What is ciprofloxacin PK under ECMO❓
❇️A 400 mg 8 -hly regimen achieved > 72% of probability of target attainment (PTA)
The full article 🔗https://t.co/cqvBnfDga8
#pharmacokinetics#FOAMecmo#ECLS
Do you want to be part of our Centre of Research Excellence to reduce the burden of antimicrobial resistance through optimal, personalised dosing (RESPOND)?
Check out this amazing PhD opportunity https://t.co/VJnWpaGtdG
Let's talk!
@jasonroberts_pk @SuzieParker_CMG @b_fekade
Well done @vesaaar and thank you @CCRG_Research & @CRE_REDUCE The ASAP ECMO Study attempts to answer antimicrobial dosing questions in patients receiving ECMO. Piperacillin/tazobactam, vancomycin and now, cefepime. More to come 👏👏👏
#AMR2019 in Brisbane @MetroNorthHHS National Level AMS session chaired by Prof Mieke van Driel from 2pm. Join us online via https://t.co/DbbHCaUnOA
@trentyarwood
@danielstefanski
@jasonroberts_pk@NCAS_Aus
Only 2 more weeks until our Antimicrobial optimisation workshop- great faculty & relevant topics. Wednesday Feb 21 in Brisbane pre @AusAntibiotics - featuring @davidantibiotic@NSchellack@padstamundo@KathrynDaveson @urbakf Profs Wilcox, Lipman & Carmeli https://t.co/5ZIq7l6YSv